Page last updated: 2024-08-26

mci 9038 and Atherogenesis

mci 9038 has been researched along with Atherogenesis in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Du, Y; He, L; Liu, Q; Wang, H; Wang, J; Xu, J; Xu, X1
Chen, HS; Cui, Y; Hou, XW; Li, XQ; Tian, XF; Wang, XH; Zhou, ZH1

Trials

1 trial(s) available for mci 9038 and Atherogenesis

ArticleYear
Safety and preliminary efficacy of argatroban plus dual antiplatelet therapy for acute mild to moderate ischemic stroke with large artery atherosclerosis.
    Brain and behavior, 2022, Volume: 12, Issue:7

    Topics: Arginine; Arteries; Atherosclerosis; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Stroke; Pipecolic Acids; Platelet Aggregation Inhibitors; Prospective Studies; Retrospective Studies; Sulfonamides; Treatment Outcome

2022

Other Studies

1 other study(ies) available for mci 9038 and Atherogenesis

ArticleYear
Dual Antiplatelet Therapy Plus Argatroban Prevents Early Neurological Deterioration in Branch Atherosclerosis Disease.
    Stroke, 2022, Volume: 53, Issue:1

    Topics: Arginine; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Humans; Pipecolic Acids; Platelet Aggregation Inhibitors; Stroke; Sulfonamides; Ticlopidine

2022